Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate‐risk acute myeloid leukemia

Marianne Hoffmann(Herlev Hospital), Hans Erik Johnsen(Herlev Hospital), Karen Dybkær(Aalborg University Hospital), Tobias Wirenfeldt Klausen(Copenhagen University Hospital), Mette Nyegaard(Statens Serum Institut), Alexander Schmitz(Chr. Hansen (Denmark)), Eva Leinøe(Rigshospitalet), Henrik Hasle(Aarhus University Hospital), Kjeld Schmiegelow(University of Copenhagen), Suzette Sørensen(North Denmark Region), Olav J. Bergmann(Hospital South West Jutland), Steffen Falgreen Larsen(Aalborg University Hospital), Martin Boegsted(Aalborg University Hospital)
Cytometry Part B Clinical Cytometry
February 10, 2012
10.1002/cyto.b.20633
Cited by 13

Related Papers

Common variants conferring risk of schizophrenia
|Nature|2009|1.7k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
|Blood|2012|575
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
|Nature Genetics|2016|473